Suppr超能文献

口下颌肌张力障碍:2020例临床检查

Oromandibular Dystonia: A Clinical Examination of 2,020 Cases.

作者信息

Scorr Laura M, Factor Stewart A, Parra Sahyli Perez, Kaye Rachel, Paniello Randal C, Norris Scott A, Perlmutter Joel S, Bäumer Tobias, Usnich Tatiana, Berman Brian D, Mailly Marie, Roze Emmanuel, Vidailhet Marie, Jankovic Joseph, LeDoux Mark S, Barbano Richard, Chang Florence C F, Fung Victor S C, Pirio Richardson Sarah, Blitzer Andrew, Jinnah H A

机构信息

Department of Neurology, Emory University, Atlanta, GA, United States.

Department of Otolaryngology, Rutgers University, Newark, NJ, United States.

出版信息

Front Neurol. 2021 Sep 16;12:700714. doi: 10.3389/fneur.2021.700714. eCollection 2021.

Abstract

The goal of this study is to better characterize the phenotypic heterogeneity of oromandibular dystonia (OMD) for the purpose of facilitating early diagnosis. First, we provide a comprehensive summary of the literature encompassing 1,121 cases. Next, we describe the clinical features of 727 OMD subjects enrolled by the Dystonia Coalition (DC), an international multicenter cohort. Finally, we summarize clinical features and treatment outcomes from cross-sectional analysis of 172 OMD subjects from two expert centers. In all cohorts, typical age at onset was in the 50s and 70% of cases were female. The Dystonia Coalition cohort revealed perioral musculature was involved most commonly (85%), followed by jaw (61%) and tongue (17%). OMD more commonly appeared as part of a segmental dystonia (43%), and less commonly focal (39%) or generalized (10%). OMD was found to be associated with impaired quality of life, independent of disease severity. On average, social anxiety (LSA score: 33 ± 28) was more common than depression (BDI II score: 9.7 ± 7.8). In the expert center cohorts, botulinum toxin injections improved symptom severity by more than 50% in ~80% of subjects, regardless of etiology. This comprehensive description of OMD cases has revealed novel insights into the most common OMD phenotypes, pattern of dystonia distribution, associated psychiatric disturbances, and effect on QoL. We hope these findings will improve clinical recognition to aid in timely diagnosis and inform treatment strategies.

摘要

本研究的目的是为了便于早期诊断,更好地描述口下颌肌张力障碍(OMD)的表型异质性。首先,我们对涵盖1121例病例的文献进行了全面总结。其次,我们描述了国际多中心队列肌张力障碍联盟(DC)纳入的727例OMD受试者的临床特征。最后,我们总结了来自两个专家中心的172例OMD受试者横断面分析的临床特征和治疗结果。在所有队列中,典型发病年龄为50多岁,70%的病例为女性。肌张力障碍联盟队列显示,口周肌肉组织受累最为常见(85%),其次是下颌(61%)和舌(17%)。OMD更常表现为节段性肌张力障碍的一部分(43%),较少表现为局灶性(39%)或全身性(10%)。研究发现,OMD与生活质量受损有关,与疾病严重程度无关。平均而言,社交焦虑(LSA评分:33±28)比抑郁(BDI II评分:9.7±7.8)更常见。在专家中心队列中,无论病因如何,约8

相似文献

1
口下颌肌张力障碍:2020例临床检查
Front Neurol. 2021 Sep 16;12:700714. doi: 10.3389/fneur.2021.700714. eCollection 2021.
2
肉毒杆菌神经毒素A治疗口下颌肌张力障碍的疗效与安全性:一项荟萃分析
J Neural Transm (Vienna). 2019 Feb;126(2):141-148. doi: 10.1007/s00702-018-1960-7. Epub 2019 Jan 2.
3
口颌肌张力障碍:肉毒毒素的长期治疗。
Laryngoscope. 2013 Dec;123(12):3078-83. doi: 10.1002/lary.23265. Epub 2013 Oct 5.
4
口下颌肌张力障碍:240例患者的人口统计学和临床数据
J Mov Disord. 2018 May;11(2):78-81. doi: 10.14802/jmd.17065. Epub 2018 May 30.
5
口颌肌张力障碍:82 例患者的临床和人口统计学数据。
Tremor Other Hyperkinet Mov (N Y). 2023 Jan 30;13:3. doi: 10.5334/tohm.730. eCollection 2023.
6
张口型和闭口型口下颌肌张力障碍的临床、病因及治疗特点:单一治疗中心十年经验
Tremor Other Hyperkinet Mov (N Y). 2014 Apr 30;4:231. doi: 10.7916/D8TH8JSM. eCollection 2014.
7
口颌肌张力障碍、精神困扰和口面功能障碍——在接受肉毒毒素治疗 8-10 年后的随访。
J Oral Rehabil. 2019 May;46(5):441-449. doi: 10.1111/joor.12768. Epub 2019 Feb 5.
9
肉毒杆菌毒素治疗口下颌肌张力障碍的系统评价
Toxicon. 2018 Jun 1;147:96-99. doi: 10.1016/j.toxicon.2018.02.006. Epub 2018 Feb 14.
10
使用肉毒杆菌毒素治疗口下颌肌张力障碍的化学去神经支配法
Cureus. 2021 Oct 1;13(10):e18425. doi: 10.7759/cureus.18425. eCollection 2021 Oct.

引用本文的文献

1
病例报告:肉毒杆菌毒素治疗 THAP1 突变患者的舌肌张力障碍症状
Dystonia. 2024;2. doi: 10.3389/dyst.2023.11361. Epub 2024 Jan 4.
2
奥曲肽治疗口下颌肌张力障碍的系统评价和荟萃分析
Toxins (Basel). 2024 Dec 16;16(12):546. doi: 10.3390/toxins16120546.
3
评估深度学习技术用于识别阈下抑郁症患者的舌部特征:一项前瞻性观察研究。
Front Psychiatry. 2024 Aug 8;15:1361177. doi: 10.3389/fpsyt.2024.1361177. eCollection 2024.
4
肉毒毒素在口腔颌面医学中的治疗用途和疗效:牙科视角。
Toxins (Basel). 2024 May 10;16(5):220. doi: 10.3390/toxins16050220.
6
口颌肌张力障碍:82 例患者的临床和人口统计学数据。
Tremor Other Hyperkinet Mov (N Y). 2023 Jan 30;13:3. doi: 10.5334/tohm.730. eCollection 2023.
7
与妥瑞氏症相关的口面运动性抽搐。
J Neurol. 2023 May;270(5):2591-2596. doi: 10.1007/s00415-023-11583-8. Epub 2023 Feb 1.
8
深部脑刺激和肉毒毒素注射治疗口下颌肌张力障碍的神经生理学基础。
Toxins (Basel). 2022 Nov 2;14(11):751. doi: 10.3390/toxins14110751.
10
口下颌肌张力障碍中肉毒杆菌神经毒素的患者选择与注射技术
Clin Park Relat Disord. 2022 Aug 5;7:100160. doi: 10.1016/j.prdoa.2022.100160. eCollection 2022.

本文引用的文献

1
口腔颌面部外科服务为基础的研究:口颌肌张力障碍的流行率和发病率。
Clin Oral Investig. 2021 Oct;25(10):5755-5764. doi: 10.1007/s00784-021-03878-9. Epub 2021 May 6.
2
肌张力障碍联盟:一个用于临床和转化研究的多中心网络。
Front Neurol. 2021 Apr 8;12:660909. doi: 10.3389/fneur.2021.660909. eCollection 2021.
3
眼睑痉挛、口下颌肌张力障碍和梅杰综合征:临床与遗传学新进展
Front Neurol. 2021 Mar 29;12:630221. doi: 10.3389/fneur.2021.630221. eCollection 2021.
4
特定疾病的口下颌肌张力障碍评定量表(OMDRS)的开发与验证
Front Neurol. 2020 Nov 3;11:583177. doi: 10.3389/fneur.2020.583177. eCollection 2020.
5
肌张力障碍的医学与外科治疗
Neurol Clin. 2020 May;38(2):325-348. doi: 10.1016/j.ncl.2020.01.003. Epub 2020 Mar 2.
6
肌张力障碍
Continuum (Minneap Minn). 2019 Aug;25(4):976-1000. doi: 10.1212/CON.0000000000000747.
7
深部脑刺激治疗梅杰综合征:一项基于个体患者数据的荟萃分析。
J Neurol. 2019 Nov;266(11):2646-2656. doi: 10.1007/s00415-019-09462-2. Epub 2019 Jul 13.
8
X 连锁型肌张力障碍帕金森病的发音和吞咽功能障碍。
Laryngoscope. 2020 Jan;130(1):171-177. doi: 10.1002/lary.27897. Epub 2019 Mar 19.
9
基于临床特征的个体化注射方法治疗舌部肌张力障碍的肉毒毒素治疗。
Toxins (Basel). 2019 Jan 17;11(1):51. doi: 10.3390/toxins11010051.
10
特发性肌张力障碍患者的生活质量:系统评价。
J Neurol. 2019 Dec;266(12):2897-2906. doi: 10.1007/s00415-018-9119-x. Epub 2018 Nov 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验